Parexel introduces FSP outsourcing model at DIA

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/shirnosov)
(Image: Getty/shirnosov)
Parexel launched a delivery model for its FSP services at DIA 2019 Global Annual Meeting in San Diego as the company aims to tailor solutions for biopharma customers.

The solutions provider announced its new outsourcing delivery model for Functional Service Provider (FSP) services to focus on patient centricity in its customer solutions. Parexel has been providing FSP services for a number of years and is now integrating its offerings with this model to provide a multifunctional resource.

Chris Baker, SVP and global head of FSP at Parexel told us,“Today’s biopharma companies are keeping the patient perspective and patient needs as the main focus is essential throughout the drug development process and improve outcomes, but they require access to the right expertise and functional services to accomplish this.”

Parexel views the launch of this model as a means of aligning the company with the changing needs of its biopharma customers looking for full service, functional, or hybrid approaches.

“Today’s drug development landscape is constantly changing, and with that, so are the needs of biopharma companies. Today’s biopharma companies need flexible and hybrid approaches to their outsourcing needs,”​ said Baker.

Through this delivery model,​ customers will have access to multifunctional resources through a single point of contact.

Parexel FSP includes more than 5,000 specialized employees worldwide with a 95% success rate in delivering repeat business.

The company’s functional service solutions include global clinical operations, global data operations, pharmacovigilance, medical affairs, medical writing, and regulatory support. The company has provided FSP in both full service and flexible clinical development services through more than 1400 projects.

Related news

Show more

Related products

show more

Local Lab Data Management

Local Lab Data Management

Q2 Solutions | 01-Jul-2020 | Technical / White Paper

When a clinical trial requires local or point-of-care laboratory testing, managing the resulting data can be a significant burden to both the sponsor and...

Laboratory Solutions for COVID-19 Clinical Trials

Laboratory Solutions for COVID-19 Clinical Trials

Q2 Solutions | 10-Jun-2020 | Clinical Study

As a leading laboratory services organization for trials across the globe, we are proud to partner with clients to support COVID-19 clinical trials. Our...

Parents as Gatekeepers for Children with Cancer

Parents as Gatekeepers for Children with Cancer

PRA Health Sciences | 08-Jun-2020 | Technical / White Paper

The RACE for Children Act will require new drugs intended for adult cancer treatment to also be studied in pediatric cancers when the molecular target...

RACE Act Prompts Pediatric Oncology Trials

RACE Act Prompts Pediatric Oncology Trials

PRA Health Sciences | 04-May-2020 | Technical / White Paper

Many providers prescribe drugs off-label to pediatric patients, even though there have been few pediatric trials for many of these drugs. In response,...

Related suppliers

Follow us

Products

View more

Webinars